Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.
Interventions
DRUGbiphasic insulin aspart 30
Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with type 2 diabetes * Treated with oral anti-diabetics and/or human insulin
Exclusion criteria
* Persons previously included in the trial * Hypersensitive to biphasic insulin aspart or any of the excipients * Pregnant or lactating women, or those who plan to get pregnant within the next 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of severe hypoglycaemic episodes | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of severe hypoglycaemic episodes | — |
| Number of mild hypoglycaemic episodes | — |
| Postprandial glucose concentration after breakfast, lunch, and dinner | — |
| Average fasting glucose concentration after waking and before main meals | — |
| Average plasma glucose level at bedtime and at night | — |
Countries
Poland
Outcome results
None listed